1. Home
  2. PCYO vs NKTR Comparison

PCYO vs NKTR Comparison

Compare PCYO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

HOLD

Current Price

$11.06

Market Cap

249.5M

Sector

Utilities

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$64.80

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCYO
NKTR
Founded
1976
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.5M
2.2B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
PCYO
NKTR
Price
$11.06
$64.80
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$146.67
AVG Volume (30 Days)
56.0K
1.2M
Earning Date
04-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
12.50
N/A
EPS
0.23
N/A
Revenue
$1,227,787.00
$307,711,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$46.57
N/A
Revenue Growth
171.54
86.00
52 Week Low
$9.65
$21.02
52 Week High
$12.44
$109.00

Technical Indicators

Market Signals
Indicator
PCYO
NKTR
Relative Strength Index (RSI) 51.37 49.36
Support Level $10.71 $64.30
Resistance Level $10.96 $66.52
Average True Range (ATR) 0.36 3.38
MACD 0.01 1.26
Stochastic Oscillator 48.15 53.70

Price Performance

Historical Comparison
PCYO
NKTR

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: